# US 2021/0261664 A1 · Composition for eliciting infectious immunological tolerance

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0261664 A1
- Document ID: US20210261664A1
- Status: Published application
- Kind: A1
- Application number: 17/254,110
- Filed: 2019-06-21
- Published: 2021-08-26
- Earliest claimed: 2018-06-22
- Assignees: Junten Bio Co., Ltd.
- Applicants: JUNTEN BIO Co., Ltd.
- Inventors: Koichiro Uchida; Kazuyoshi Takeda; Ko Okumura
- Web page: https://patentgrep.com/patent/US20210261664A1

## CPC

- C07K 16/2818: {against CD28 or CD152}
- A61K 39/001: {Preparations to induce tolerance to non-self, e.g. prior to transplantation}
- A61K 39/35: Allergens
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/22: Immunosuppressive or immunotolerising
- A61K 40/418: {Antigens related to induction of tolerance to non-self}
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- C12N 5/0637: {Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg}
- A61K 2039/505: {comprising antibodies}
- A61K 2239/38: characterised by the dose, timing or administration schedule
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C12N 2501/51: B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure provides a novel technique relating to immunological tolerance. More specifically, the present inventor found for the first time that, in a technique for inducing immunological tolerance by administering to an organ transplantation patient (a recipient) a cell preparation containing cells in which anergy is induced by an inhibitor inhibiting the interaction between CD80/CD86 and CD28, the immunological tolerance continues even after the disappearance of the cells derived from the cell preparation from the recipient (infectious immunological tolerance). Further, the present inventor proved that such a cell preparation can elicit immunological tolerance against immunological rejection caused by allergy, iPS cells, etc. or cells, tissues or organs derived therefrom.

## Claims

### Claim at position 1

-44. (canceled)

### Claim 45

A method of eliciting permanent immune tolerance (infectious immune tolerance) to a donor in a subject, the method comprising administering to the subject an effective amount of a cell in which immune tolerance has been induced by a step that comprises mixing (i) an inhibitory factor that can inhibit an interaction between CD80 and/or CD86 and CD28, (ii) a cell derived from the subject, and (iii) an antigen derived from the donor or a composition comprising an antigen from the donor.

### Claim 46 (depends on 45)

The method of claim 45, wherein the immune tolerance is immune tolerance elicited in a CD8 positive T cell in the subject.

### Claim 47 (depends on 45)

The method of claim 45, wherein the inhibitory factor is selected from a small molecule, a protein, a nucleic acid, a lipid, a saccharide, and a combination thereof.

### Claim 48 (depends on 47)

The method of claim 47, wherein the protein is an antibody or a variant thereof, or a cell surface molecule or a variant thereof.

### Claim 49 (depends on 48)

The method of claim 48, wherein the variant of the antibody is an antigen binding fragment.

### Claim 50 (depends on 48)

The method of claim 48, wherein the variant of the cell surface molecule is a fusion protein.

### Claim 51 (depends on 45)

The method of claim 45, wherein the inhibitory factor is selected from an anti-CD80 antibody, an anti-CD86 antibody, a bispecific antibody to CD80 and CD86, an anti-CD28 antibody or an antigen binding fragment thereof, a CTLA4-Ig fusion protein, and a CD28-Ig fusion protein.

### Claim 52 (depends on 51)

The method of claim 51, wherein the CTLA4-Ig fusion protein is abatacept or belatacept.

### Claim 53 (depends on 45)

The method of claim 45, wherein the method is for suppressing or preventing immune rejection caused by an iPS cell or an ES cell or a cell, tissue, or organ derived therefrom in the subject, and wherein the antigen derived from the donor is an antigen derived from said iPS cell or said ES cell.

### Claim 54 (depends on 45)

The method of claim 45, wherein the method is for treating or preventing allergy in the subject, and wherein the antigen derived from the donor is an antigen which is a cause of said allergy.

### Claim 55

A method of treating or preventing a disease, disorder, or condition in a subject wherein the disease, disorder, or condition is caused by an antigen that is not derived from the subject, the method comprising administering to the subject an effective amount of a cell in which immune tolerance has been induced by a step that comprises mixing (i) an inhibitory factor that can inhibit an interaction between CD80 and/or CD86 and CD28, (ii) a cell derived from the subject, and (iii) one of (a) an antigen that is derived from the subject, (b) an antigen that is not derived from the subject, or (c) a composition comprising the antigen of (a) or (b).

### Claim 56 (depends on 55)

The method of claim 55, wherein the disease, disorder, or condition is selected from graft rejection, allergy, autoimmune disease, graft-versus-host disease, and immune rejection caused by transplantation of an iPS cell or an ES cell or a cell, tissue, or organ derived therefrom.

### Claim 57 (depends on 55)

The method of claim 55, wherein the disease, disorder, or condition is allergy, and wherein the antigen derived from the subject or the antigen that is not derived from the subject is an antigen which is a cause of allergy.

### Claim 58 (depends on 57)

The method of claim 57, wherein the antigen which is a cause of allergy is selected from an antigen associated with food, an antigen associated with pollen, an antigen associated with a drug, and an antigen associated with a metal.

### Claim 59 (depends on 55)

The method of claim 55, wherein the disease, disorder, or condition is immune rejection caused by transplantation of an iPS cell or an ES cell or a cell, tissue, or organ derived therefrom, and wherein the antigen derived from the subject or the antigen that is not derived from the subject is an antigen derived from said iPS cell or said ES cell.
